WilmerHale Advises Catabasis Pharmaceuticals in Pricing of $20M Underwritten Public Offering

WilmerHale Advises Catabasis Pharmaceuticals in Pricing of $20M Underwritten Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On February 6, 2019, Catabasis Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a public offering price of $5.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 4,000,000 shares of common stock and warrants to purchase 2,000,000 shares of common stock. Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.

The WilmerHale team representing Catabasis is led by Rosemary Reilly and includes Jeffries Oliver-Li, Jasmine Haddad and Victoria Hartmann.

Read more about the offering.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel